prednisone has been researched along with HIV Wasting Syndrome in 2 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
HIV Wasting Syndrome: Involuntary weight loss of greater than 10 percent associated with intermittent or constant fever and chronic diarrhea or fatigue for more than 30 days in the absence of a defined cause other than HIV infection. A constant feature is major muscle wasting with scattered myofiber degeneration. A variety of etiologies, which vary among patients, contributes to this syndrome. (From Harrison's Principles of Internal Medicine, 13th ed, p1611).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In an exploratory study of virologic and immunomodulatory effects of corticosteroid therapy for wasting syndrome, four HIV-infected adults with recent unexplained weight loss were given tapering doses of prednisone over a 2-month period." | 9.08 | Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss. ( Bucy, RP; Kilby, JM; Mulanovich, V; Saag, MS; Shaw, GM; Tabereaux, PB, 1997) |
| "In an exploratory study of virologic and immunomodulatory effects of corticosteroid therapy for wasting syndrome, four HIV-infected adults with recent unexplained weight loss were given tapering doses of prednisone over a 2-month period." | 5.08 | Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss. ( Bucy, RP; Kilby, JM; Mulanovich, V; Saag, MS; Shaw, GM; Tabereaux, PB, 1997) |
| " Patients with polyarteritis nodosa (two) or polymyositis (one) were treated with prednisone, which improved their wasting syndrome." | 3.69 | Skeletal muscle studies in patients with HIV-related wasting syndrome. ( Casademont, J; Cebrián, M; Grau, JM; Mallolas, J; Masanés, F; Miró, O; Pedrol, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miró, O | 1 |
| Pedrol, E | 1 |
| Cebrián, M | 1 |
| Masanés, F | 1 |
| Casademont, J | 1 |
| Mallolas, J | 1 |
| Grau, JM | 1 |
| Kilby, JM | 1 |
| Tabereaux, PB | 1 |
| Mulanovich, V | 1 |
| Shaw, GM | 1 |
| Bucy, RP | 1 |
| Saag, MS | 1 |
1 trial available for prednisone and HIV Wasting Syndrome
| Article | Year |
|---|---|
Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss.
Topics: Adult; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Female; HIV Wasting Syndrome; Humans; | 1997 |
1 other study available for prednisone and HIV Wasting Syndrome
| Article | Year |
|---|---|
Skeletal muscle studies in patients with HIV-related wasting syndrome.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biopsy; Female; HIV Wasting Syndrome; Humans; Immunos | 1997 |